The progression of cardiometabolic disease

Validation of a new cardiometabolic disease staging system applicable to obesity

Fangjian Guo, Douglas R. Moellering, W. Timothy Garvey

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective To validate a Cardiometabolic Disease Staging (CMDS) system for assigning risk level for diabetes, and all-cause and cardiovascular disease (CVD) mortality. Design and Methods Two large national cohorts, CARDIA and NHANES III, were used to validate CMDS. CMDS: Stage 0: metabolically healthy; Stage 1: one or two metabolic syndrome risk factors [other than impaired fasting glucose (IFG)]; Stage 2: IFG or impaired glucose tolerance (IGT) or metabolic syndrome (without IFG); Stage 3: two of three (IFG, IGT, and/or metabolic syndrome); and Stage 4: type 2 diabetes mellitus/CVD. Results In the CARDIA study, compared with Stage 0 metabolically healthy subjects, adjusted risk for diabetes exponentially increased from Stage 1 [hazard ratio (HR) 2.83, 95% confidence interval (CI): 1.76-4.55], to Stage 2 (HR 8.06, 95% CI 4.91-13.2), to Stage 3 (HR 23.5, 95% CI 13.7-40.1) (P for trend

Original languageEnglish (US)
Pages (from-to)110-118
Number of pages9
JournalObesity
Volume22
Issue number1
DOIs
StatePublished - Jan 2014
Externally publishedYes

Fingerprint

Disease Progression
Fasting
Obesity
Glucose
Glucose Intolerance
Confidence Intervals
Cardiovascular Diseases
Nutrition Surveys
Type 2 Diabetes Mellitus
Healthy Volunteers
Mortality

ASJC Scopus subject areas

  • Endocrinology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

The progression of cardiometabolic disease : Validation of a new cardiometabolic disease staging system applicable to obesity. / Guo, Fangjian; Moellering, Douglas R.; Garvey, W. Timothy.

In: Obesity, Vol. 22, No. 1, 01.2014, p. 110-118.

Research output: Contribution to journalArticle

@article{3103b4be1773404fb1fcd200c2d36c21,
title = "The progression of cardiometabolic disease: Validation of a new cardiometabolic disease staging system applicable to obesity",
abstract = "Objective To validate a Cardiometabolic Disease Staging (CMDS) system for assigning risk level for diabetes, and all-cause and cardiovascular disease (CVD) mortality. Design and Methods Two large national cohorts, CARDIA and NHANES III, were used to validate CMDS. CMDS: Stage 0: metabolically healthy; Stage 1: one or two metabolic syndrome risk factors [other than impaired fasting glucose (IFG)]; Stage 2: IFG or impaired glucose tolerance (IGT) or metabolic syndrome (without IFG); Stage 3: two of three (IFG, IGT, and/or metabolic syndrome); and Stage 4: type 2 diabetes mellitus/CVD. Results In the CARDIA study, compared with Stage 0 metabolically healthy subjects, adjusted risk for diabetes exponentially increased from Stage 1 [hazard ratio (HR) 2.83, 95{\%} confidence interval (CI): 1.76-4.55], to Stage 2 (HR 8.06, 95{\%} CI 4.91-13.2), to Stage 3 (HR 23.5, 95{\%} CI 13.7-40.1) (P for trend",
author = "Fangjian Guo and Moellering, {Douglas R.} and Garvey, {W. Timothy}",
year = "2014",
month = "1",
doi = "10.1002/oby.20585",
language = "English (US)",
volume = "22",
pages = "110--118",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The progression of cardiometabolic disease

T2 - Validation of a new cardiometabolic disease staging system applicable to obesity

AU - Guo, Fangjian

AU - Moellering, Douglas R.

AU - Garvey, W. Timothy

PY - 2014/1

Y1 - 2014/1

N2 - Objective To validate a Cardiometabolic Disease Staging (CMDS) system for assigning risk level for diabetes, and all-cause and cardiovascular disease (CVD) mortality. Design and Methods Two large national cohorts, CARDIA and NHANES III, were used to validate CMDS. CMDS: Stage 0: metabolically healthy; Stage 1: one or two metabolic syndrome risk factors [other than impaired fasting glucose (IFG)]; Stage 2: IFG or impaired glucose tolerance (IGT) or metabolic syndrome (without IFG); Stage 3: two of three (IFG, IGT, and/or metabolic syndrome); and Stage 4: type 2 diabetes mellitus/CVD. Results In the CARDIA study, compared with Stage 0 metabolically healthy subjects, adjusted risk for diabetes exponentially increased from Stage 1 [hazard ratio (HR) 2.83, 95% confidence interval (CI): 1.76-4.55], to Stage 2 (HR 8.06, 95% CI 4.91-13.2), to Stage 3 (HR 23.5, 95% CI 13.7-40.1) (P for trend

AB - Objective To validate a Cardiometabolic Disease Staging (CMDS) system for assigning risk level for diabetes, and all-cause and cardiovascular disease (CVD) mortality. Design and Methods Two large national cohorts, CARDIA and NHANES III, were used to validate CMDS. CMDS: Stage 0: metabolically healthy; Stage 1: one or two metabolic syndrome risk factors [other than impaired fasting glucose (IFG)]; Stage 2: IFG or impaired glucose tolerance (IGT) or metabolic syndrome (without IFG); Stage 3: two of three (IFG, IGT, and/or metabolic syndrome); and Stage 4: type 2 diabetes mellitus/CVD. Results In the CARDIA study, compared with Stage 0 metabolically healthy subjects, adjusted risk for diabetes exponentially increased from Stage 1 [hazard ratio (HR) 2.83, 95% confidence interval (CI): 1.76-4.55], to Stage 2 (HR 8.06, 95% CI 4.91-13.2), to Stage 3 (HR 23.5, 95% CI 13.7-40.1) (P for trend

UR - http://www.scopus.com/inward/record.url?scp=84892368688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892368688&partnerID=8YFLogxK

U2 - 10.1002/oby.20585

DO - 10.1002/oby.20585

M3 - Article

VL - 22

SP - 110

EP - 118

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 1

ER -